ARS Pharmaceuticals is a biopharmaceutical company that commercializes neffy, a needle-free epinephrine nasal spray for treating Type I allergic reactions and anaphylaxis. The product uses a proprietary absorption enhancer to enable safe intranasal delivery and is approved in the United States, European Union, and other key markets. The company generates revenue through direct U.S. sales via a dedicated sales force and pharmaceutical wholesalers, as well as through international licensing partnerships with major distributors in Japan, China, Australia, and Canada, targeting millions of patients who either currently use epinephrine autoinjectors, have lapsed prescriptions, or remain unmedicated despite allergic risk.